Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
Prof. Francisco Fernandez-Aviles,
In this session, prestigious experts in the field provided a comprehensive update on the most critical aspects of stem cell therapy for cardiac regeneration and repair.
Prof. Bartunek, from Aalst, Belgium, discussed the potential of different somatic cells, highlighting the importance of paracrine factors to improve resident and transplanted cell performance and the promising role of the new family of guided cardiopoietic cells.
Prof. Anthony Marhur, from London, UK, comprehensively reviewed the different methods of cell delivery existing to date, emphasising the already well-established feasibility and safety of intracoronary delivery using a simple PCI-like approach and the percutaneous intramyocardial delivery through the NOGA system.
The lecture by Prof. Lipiecki, from Paris, France, focused on cell transplantation delivery during cardiac surgery, highlighting the safety of this approach and the promising results of bone marrow cells in this setting.
Finally, Prof. Andreas Zeiher, from Frankfurt, Germany, provided a critical overview of clinical trials. It seems to be clear that clinical application of stem cell therapies for cardiac repair is feasible and safe, with a benefit that depends on cell product, method of delivery and clinical setting. In patients with STEMI, early IC application has a favorable risk-benefit ratio and fulfils criteria for large-scale randomized clinical trials. In chronic patients, navigator-guided transendocardial delivery is feasible and safe. The quest for the “ideal” cell is still ongoing.
In summary, together with basic research, this innovation requires parallel translational investigation based on large animal models and phase 1-2 clinical trials to explore other scenarios and cells and to answer specific questions (cell processing, biological efficacy, dose, timing, associations, delivery and guiding, etc)
Cell transplantation for myocardial regeneration
This congress report accompanies a presentation given at the ESC Congress 2009. Written by the author himself/herself, this report does not necessarily reflect the opinion of the European Society of Cardiology.
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved